United Therapeutics (UTHR) Corporation announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of Shareholders, scheduled for June 26, 2026. Prof. Dwek joined the United Therapeutics Board in 2002. With this change, the company’s Board of Directors approved a reduction in its size from 13 members to 12, effective at the 2026 Annual Meeting of Shareholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- United Therapeutics price target raised to $519 from $471 at Morgan Stanley
- United Therapeutics initiated with an Outperform at Raymond James
- United Therapeutics announces FDA granted RMAT designation to miroliverELAP
- United Therapeutics price target raised to $700 from $643 at RBC Capital